Marty Makary: “We've identified ways that we can streamline that process as…”

“And we think we can also shave off some of the time that it takes for the FDA to approve biosimilars. We've identified ways that we can streamline that process as we are with other drugs. So you're correct in that some of those waivers have been issued. So we are going to make it very clear now and offer clear guidance with Humira.” (24:52–24:58)

This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.